The Chorus Trial
The Chorus Trial
Welcome to the CHORUS trial. CHORUS is a multi-centre double-blind randomised placebo-controlled group-sequential superiority trial to assess the effectiveness and cost-effectiveness of oral Corticosteroids in patients witH fibrOtic hypeRsensitivity pneUmonitiS (CHORUS).
Fibrotic hypersensitivity pneumonitis (FHP) is a devastating lung disease involving inflammation and scarring in the lungs. There are currently no guidelines for treating FHP. Most people who are diagnosed with FHP are prescribed a course of corticosteroids (‘steroids’). However, there is no good evidence to say that treating FHP with steroids is the best thing to do. Therefore we are undertaking a randomised controlled trial to find out if the commonly prescribed steroid called prednisolone is effective and safe for people with FHP.
The CHORUS trial is led by Prof Michael Gibbons (Chief Investigator) and Dr Philip Molyneaux (Co-Lead) and is sponsored by the Royal Devon University Hospitals NHS Foundation Trust (RDUH). The trial is funded by the National Institute for Health Research (NIHR155220). The trial is managed by the Exeter Clinical Trials Unit (ExeCTU).
A scientific summary about the trial can be found on the NIHR webpages via this link.
Contact the Trial team for further information: chorus@exeter.ac.uk